#USA #Boston #TTX-MC138 #TransCode Therapeutics #Oncology Portfolio

Strategic Review by TransCode Therapeutics

TransCode Therapeutics, Inc. (Nasdaq: RNAZ) has officially engaged Tungsten Advisors to conduct a thorough strategic review aimed at maximizing the value of its oncology portfolio, particularly focusing on its leading candidate, TTX-MC138. This clinical-stage biopharmaceutical company is dedicated to innovating RNA-based therapeutics and immuno-oncology treatments for advanced cancers.

The strategic process is anticipated to thoroughly explore a variety of potential avenues for TransCode, including licensing agreements, asset sales, and new partnerships in development and commercialization. This comprehensive evaluation intends to uncover opportunities that would enhance the overall value of the company's offerings in the oncology sector.

What is TTX-MC138?

TTX-MC138 is an investigational therapeutic agent engineered to target and inhibit microRNA-10b (miR-10b), a molecule that plays a critical role in the survival and progression of metastatic cancer cells. This candidate is currently undergoing Phase 2a clinical trials specifically for patients with circulating tumor DNA (ctDNA) positive colorectal cancer following curative-intent treatment. This trial is being executed in partnership with the Quantum Leap Healthcare Collaborative within its innovative PRE-I-SPY program.

The latest findings from the Phase 1a trial indicate encouraging safety data and a notable number of patients achieving stable disease outcomes. CEO Philippe P. Calais expressed optimism about the strategic process, asserting its potential to support ongoing development efforts for TTX-MC138 while maximizing shareholder value. This indicates a proactive approach by TransCode to ensure that the clinical advancements of TTX-MC138 not only continue but thrive as they search for collaborations and strategic opportunities.

Collaboration with Natera

In conjunction with the internal strategic review, TransCode has also forged a collaboration with Natera, Inc. This partnership aims to enhance patient enrollment in the ongoing Phase 2a clinical trial by utilizing Natera's advanced Signatera molecular residual disease test to identify suitable participants who are ctDNA positive, despite showing no imaging evidence of active disease. This collaboration is part of TransCode's broader strategy to streamline trial enrollment processes and improve patient identification.

Looking Ahead

While the strategic review is in progress, TransCode cautions that there are no guarantees it will lead to specific transactions or outcomes. The company will remain tight-lipped on progress updates unless a significant transaction is approved by the Board of Directors or disclosure becomes necessary.

TransCode Therapeutics, pioneering in the areas of immuno-oncology and targeted cancer therapies, has a dedicated portfolio of unique first-in-class therapeutic candidates. As the company navigates this strategic initiative, stakeholders will be keenly observing its developments, particularly in relation to TTX-MC138's potential and broader implications for cancer treatment.

In summary, the ongoing collaboration and strategic review by TransCode Therapeutics exemplify a structured approach to advancing its technological innovations, potentially facilitating significant developments in the treatment of advanced malignancies. For more details, please visit TransCode Therapeutics.